Literature DB >> 26489412

[The epigenome. Target for innovative therapies in head and neck carcinoma].

A Leipold1, J Hess, K Zaoui.   

Abstract

BACKGROUND: The pathogenesis of head and neck squamous carcinoma (HNSCC) is a complex and multistage process, which is characterized by the accumulation of genetic and epigenetic aberrations. Most of our knowledge concerning the regulation of gene expression by the epigenome is based on changes in DNA methylation and post-translational histone modifications that affect the phenotypic plasticity of cells under physiological and pathological conditions. STATE OF THE ART: Numerous experimental studies have unraveled the impact of epigenetic alterations during initiation and malignant progression of HNSCC and substantiate their contribution in the context of tumor stem cells and treatment resistance. Due to their stability epigenetic modifications serve as promising diagnostic and prognostic biomarkers, and the reversible nature makes key regulators attractive targets for innovative treatment options.

Entities:  

Mesh:

Year:  2015        PMID: 26489412     DOI: 10.1007/s00106-015-0075-9

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  39 in total

1.  Too many roads not taken.

Authors:  Aled M Edwards; Ruth Isserlin; Gary D Bader; Stephen V Frye; Timothy M Willson; Frank H Yu
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

Review 2.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

Review 3.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 4.  Discovery and development of SAHA as an anticancer agent.

Authors:  P A Marks
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 5.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

6.  A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.

Authors:  Jhanelle E Gray; Eric Haura; Alberto Chiappori; Tawee Tanvetyanon; Charles C Williams; Mary Pinder-Schenck; Julie A Kish; Jenny Kreahling; Richard Lush; Anthony Neuger; Leticia Tetteh; Angela Akar; Xiuhua Zhao; Michael J Schell; Gerold Bepler; Soner Altiok
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

7.  Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.

Authors:  Matthias Lechner; Tim Fenton; James West; Gareth Wilson; Andrew Feber; Stephen Henderson; Christina Thirlwell; Harpreet K Dibra; Amrita Jay; Lee Butcher; Ankur R Chakravarthy; Fiona Gratrix; Nirali Patel; Francis Vaz; Paul O'Flynn; Nicholas Kalavrezos; Andrew E Teschendorff; Chris Boshoff; Stephan Beck
Journal:  Genome Med       Date:  2013-02-05       Impact factor: 11.117

8.  Transcriptional repression of E-cadherin by human papillomavirus type 16 E6.

Authors:  Zarina J D'Costa; Carol Jolly; Elliot J Androphy; Andrew Mercer; Charles M Matthews; Merilyn H Hibma
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

9.  Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.

Authors:  Fernanda S Giudice; Decio S Pinto; Jacques E Nör; Cristiane H Squarize; Rogerio M Castilho
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

Review 10.  DNA methyltransferases: a novel target for prevention and therapy.

Authors:  Dharmalingam Subramaniam; Ravi Thombre; Animesh Dhar; Shrikant Anant
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.